New CAR T-Cell therapy shows promise for kids with tough leukemia

NCT ID NCT05480449

Recruiting now Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new version of CAR T-cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target cancer cells. The trial aims to see if this new manufacturing method is safe and effective for up to 115 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: humanized CD19-directed chimeric antigen receptor T-cells (huCART19)
What this could lead to: If successful, this could provide a more effective and safer treatment option for children with hard-to-treat B-cell acute lymphoblastic leukemia.
What could go wrong: This is an early-phase trial (Phase 1/2b), so the treatment may not work for everyone and could cause serious side effects like cytokine release syndrome or neurological issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) B LINEAGE LYMPHOBLASTIC LYMPHOMA

Contacts and locations

Locations

Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.